Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To evaluate prospective changes in psychological function among menopausal women using continuous nitroglycerin for hot flashes and examine repeated associations between psychological symptoms and hot flashes.
Methods: Menopausal women with ≥7 hot flashes/day were randomized to continuous transdermal nitroglycerin (0.2-0.4 mg/h) or placebo for 12 weeks. Psychological function was evaluated using the Center for Epidemiologic Studies-Depression Scale (CES-D), Generalized Anxiety Disorders-7 (GAD-7), and Menopause-Specific Quality of Life (MENQOL) Psychosocial Subscale. Linear mixed models examined treatment effects on mood symptoms from baseline to 5 and 12 weeks. Based on validated 7-day hot flash diaries, additional models examined associations between mood symptoms and hot flash frequency in both groups combined.
Results: Among the 141 randomized participants (mean 10.8±3.5 hot flashes/day), nitroglycerin therapy did not improve CES-D or GAD-7 scores (prespecified secondary outcomes) from baseline to 5 and 12 weeks compared with placebo. Greater hot flash frequency was associated with worse GAD-7 scores across all timepoints (β=0.05 per 1 hot flash, P =0.005), but no associations between hot flashes and CES-D or MENQOL Psychosocial scores were observed. Improvement in hot flash frequency was associated with improvement in MENQOL Psychosocial score (β=0.04 per 1 hot flash, P =0.03), but no associations between improvements in hot flashes and improvements in GAD-7 or CES-D scores were detected.
Conclusions: In a randomized trial of continuous nitroglycerin, improvements in hot flash frequency did not consistently translate into improvements in mood. Clinicians caring for women with overlapping hot flashes and mood symptoms should consider other factors influencing midlife psychological function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12313417 | PMC |
| http://dx.doi.org/10.1097/GME.0000000000002556 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Views of Menopause and Hormone Therapy Associations with Hormone Therapy Use in US Women Aged 50-79.
Womens Health Rep (New Rochelle)
September 2025
The Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
Objective: To explore symptoms, knowledge levels, perceptions, and use related to menopause and hormone therapy (HT) and to examine the factors associated with HT use and HT perceptions in perimenopausal and postmenopausal women.
Materials And Methods: We used a sample of 98 perimenopausal and postmenopausal women who aged 50-79 and participated in the Sex, ApoE-4, γ-aminobutyric acid, and Episodic memory (SAGE) study ( = 64.24, = 7.
Increased and sustained physical activity in postmenopausal women: 2-year follow-up of a resistance training intervention.
Maturitas
August 2025
Unit of Physiotherapy, Division of Prevention, Rehabilitation and Community Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. Electronic address:
Objectives: To assess whether levels of physical activity can be modified and sustained for 2 years in postmenopausal women with initially low physical activity levels participating in a randomised controlled trial.
Study Design: Postmenopausal women with vasomotor symptoms and low activity levels were randomised to a 15-week supervised full-body resistance training program three times/week or a control group maintaining low activity. After the intervention, controls were offered an introductory resistance training session and 15-week gym membership.
FDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option.
Ann Med Surg (Lond)
September 2025
Department of Medicine, Georgia State University, Atlanta, USA.
Menopausal vasomotor symptoms (VMS), such as hot flashes and night sweats, significantly impact the quality of life for many women. While hormone therapy remains a standard treatment, it is not suitable for all patients due to contraindications, safety concerns, or personal preferences. Fezolinetant (Veozah), a non-hormonal neurokinin-3 receptor (NK3R) antagonist, has emerged as a novel alternative for managing moderate to severe menopausal VMS.
View Article and Find Full Text PDFGonadotropin trajectories among postmenopausal women not using hormone therapy.
Menopause
September 2025
Department of Epidemiology and Environmental Health, State University of New York at Buffalo, Buffalo, NY.
Objective: While evidence suggests that gonadotropins may play an important role in aging-related changes in body composition and health outcomes, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) patterns have not been well characterized in older women. We characterized patterns of FSH and LH change over time after menopause.
Methods: In a sample of 291 postmenopausal women from the Women's Health Initiative OsteoPerio study who were not using hormone therapy, we estimated FSH and LH trajectories over a 20-year period using group-based trajectory modeling.
A randomized controlled trial comparing mobile-app-based cognitive behavioral therapy with and without therapist support versus face-to-face therapy: study protocol.
Eur J Obstet Gynecol Reprod Biol
August 2025
Fakher Mechatronic Research Center, Kerman University of Medical Sciences, Kerman, Iran; Research Management Centre, INTI International University, Putra Nilai, Malaysia. Electronic address:
Background: Hot flashes and night sweats (HFNS), the primary symptoms of the menopausal transition, can greatly affect women's quality of life. There is substantial evidence that cognitive-behavioral interventions positively influence the management of HFNS in women.
Objective: The aim of this study is to evaluate the effectiveness of a mobile-app-based cognitive-behavioral therapy (Meno-iCBT) on the problem rating of hot flashes and night sweats (HFNS).